What did Argenica Therapeutics (ASX:AGN) announce regarding its stroke trial?

Argenica Therapeutics has established a Clinical Advisory Committee (CAC) composed of global medical experts to oversee its upcoming Phase 2b clinical trial.

Why is the new advisory committee important for Argenica Therapeutics (ASX:AGN) shareholders?

The committee includes world-renowned stroke experts like Professors Geoffrey Donnan and Jeffrey Saver, which adds significant institutional credibility to the Phase 2b trial.

What is the current regulatory status of ARG-007 in Europe?

In early 2026, the European Medicines Agency (EMA) granted Argenica a full paediatric waiver for ARG-007. This is a major regulatory win because it allows the company to focus exclusively on adult clinical trials without the requirement for separate pediatric studies, significantly shortening the time to potential market approval in Europe.

How much cash does Argenica Therapeutics (ASX:AGN) have to fund its operations?

Argenica currently holds pro-forma cash reserves of approximately $9 million. This balance was recently bolstered by a $4 million R&D tax incentive rebate from the Australian government, providing the necessary "runway" to advance the ARG-007 program through its next clinical milestones.

What were the key takeaways from the recent Phase 2 SEANCON trial data?

The Phase 2 SEANCON trial results for ARG-007 were highly regarded by the scientific community, earning a "Best Poster Finalist" spot at the 2026 European Stroke Organisation Conference.

Argenica forms expert committee for Phase 2b trial

Written by Liezl GambePublished May. 14 2026Last Updated May. 14 2026

Argenica Therapeutics (ASX:AGN) has formed a high-level Clinical Advisory Committee to spearhead its upcoming Phase 2b trial for the neuroprotective candidate, ARG-007.

The move aims to optimise the trial’s framework, focusing on refined patient selection and dosing strategies to maximise the likelihood of clinical success in treating acute ischaemic stroke.

The committee features a formidable lineup of global authorities, including Professors Geoffrey Donnan and Jeffrey Saver, alongside consumer advocate Tony Rolfe, ensuring that the development remains aligned with both clinical excellence and patient needs.

The announcement follows a series of milestones that have bolstered the company’s regulatory and scientific standing.

In early 2026, the European Medicines Agency granted a full paediatric waiver for ARG-007, significantly streamlining the drug’s pathway to the European market.

Furthermore, data presented at the 2026 European Stroke Organisation Conference underscored the drug’s potential, with the Phase 2 SEANCON trial results being recognised as a best poster finalist.

Argenica remains well-positioned to fund these critical advancements, bolstered by a recent $4 million R&D tax incentive rebate that brought pro-forma cash reserves to $9 million.

Managing Director Dr Liz Dallimore emphasised that the committee’s deep expertise in neuroimaging and late-stage development will be "critical" as the company transitions into this pivotal clinical phase.

At the time of reporting, Argenica Therapeutics’ share price was $0.16.